Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Direct Antimicrobial Susceptibility Testing on Clinical Urine Samples by Optical Tracking of Single Cell Division Events
Zhang, Fenni , Jiang, Jiapei, McBride, Michelle, Yang, Yunze , Mo, Manni , Iriya, Rafael , Peterman, Joseph, Jing, Wenwen , Haydel, Shelley E. , Tao, Nongjian , Grys, Thomas, Zhang, Fenni , Haydel, Shelley E , Jing, Wenwen , Grys, Thomas E. , Wang, Shaopeng

Mayo Clinic

Small | November 30, 2020 | Volume: 16 | Issue: 52 | Pages: No page available

10.1002/smll.202004148 | PMID 33252191 Get It

Abstract With the increasing prevalence of antibiotic resistance, the need to develop antimicrobial susceptibility testing (AST) technologies is urgent. The current challenge has been to perform the antibiotic susceptibility testing in short time, directly with clinical samples, and with antibiotics over a broad dynamic range of clinically relevant concentrations. Here, a technology for point‐of‐care diagnosis of antimicrobial‐resistant bacteria in urinary tract infections, by imaging the clinical urine samples directly with an innovative large volume solution scattering imaging (LVSi) system and analyzing the image sequences with a single‐cell division tracking method is developed. The high sensitivity of single‐cell division tracking associated with large volume imaging enables rapid antibiotic susceptibility testing directly on the clinical urine samples. The results demonstrate direct detection of bacterial infections in 60 clinical urine samples with a 60 min LVSi video, and digital AST of 30 positive clinical samples with 100% categorical agreement with both the clinical culture results and the on‐site agar plating validation results. This technology provides opportunities for precise antibiotic prescription and proper treatment of the patient within a single clinic visit.
Insights from Twitter about novel COVID-19 symptoms
Krittanawong, Chayakrit , Narasimhan, Bharat , Narasimhan, Harish , Tang, W.H. Wilson , Tang, W H Wilson , Virk, Hafeez Ul Hassan , Wang, Zhen

Mayo Clinic

European Heart Journal - Digital Health | November 30, 2020 | Volume: 1 | Issue: 1 | Pages: 4-5

10.1093/ehjdh/ztaa003 | PMID 34192272 Get It

A genome-wide association study identifies novel genetic loci associated with pulmonary embolism
Krittanawong, Chayakrit , Narasimhan, Bharat , Hahn, Joshua , Wang, Z , Tang, Wei , Baber, Usman, Johnson, Kipp W. , Tang, W, Baber, Usman , Amos, Christopher I.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2274 Get It

Abstract Background Pulmonary embolism (PE) is a life-threatening cardiovascular condition. Studies showed that PE patients were associated with disorders of lipid metabolism and had higher triglyceride and lower HDL-C levels compared with healthy. We conducted the genome-wide association study to identify novel loci contributing to PE. Methods We conducted a large-scale GWAS of PE in 5,466 PE cases and 461,219 controls of European ancestry from the UK Biobank (466,685 participants total). We used genome-wide summary statistics to test for enrichment of functional annotations using ENRICHR. Example pathways included in Enrichr for testing include membership of genes in pathway databases such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), Wikipathway, PANTHER, BioCarta or NCI-Nature pathways. We analyzed the pathways using combined score and p-values which were well validated by comparing to several methods. For pathway analyses, we considered a nominal P-value threshold of 0.05. Results We identified genome-wide significant genetic associations in 63 independent genetic loci for PE (P<5.0x10–7). Our findings for top pathways highlight that lipid metabolism (LIPC, LCAT, NPC2), caffeine metabolism (NAT2), and sudden cardiac death (ABCG8) related genetic loci play an important role in PE alongside genes already associated with coagulation-thrombosis pathway (VWF, THPO, PTPN11, INPP5D, UROS, HMBS) (all p-values p-values <0.05). Conclusion Our findings uncovered unexpected novel factors of PE etiology, suggesting novel mechanistic concepts of PE pathophysiology. Funding Acknowledgement Type of funding source: None
Ten-year all-cause death in elderly patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: a prespecified subgroup analysis of the SYNTAX Extended Survival study
Ono, Masahiro , Hara, Hironori , Gao, Chao , Wang, R, Kappetein, P, Mohr, F. W. , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Davierwala, Piroze , Head, Stuart J., Thuijs, Daniel J.F.M. , Takahashi, Ken , Onuma, Yoshinobu , Serruys, Patrick W.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.1490 Get It

Abstract Background Coronary artery disease is the leading cause of death among elderly men and women worldwide. The aging society worldwide will lead to increasing numbers of elderly patients with multivessel coronary artery disease. Although age is recognized as one of the most important factors in a decision-making for revascularization of multivessel coronary artery disease, the very long-term outcomes in patients undergoing revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is still unclear. Objectives The aim of the present study was to investigate the association between revascularization strategies and 10-year outcomes in elderly patients. Methods The SYNTAX Extended Survival (SYNTAXES) study (NCT 03417050) is an investigator-driven extension of follow-up of a multicentre, randomised controlled trial done in 85 hospitals across 18 North American and European countries, enrolling 1,800 patients with de novo three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to revascularization strategy with CABG versus PCI in the SYNTAX trial. Patients were divided into two groups according to the prespecified threshold of 70 years old; elderly patients (>70 years) and non-elderly patients (≤70 years). The primary endpoint of this study was all-cause death at 10 years. Results Out of 1,800 patients, 575 patients (31.9%) were classified as elderly (>70 years). The mean age ± standard deviation (SD) of the elderly patients and the non-elderly patients was 75.8±3.6 years and 60.1±7.4 years, respectively. Of note, elderly patients were more frequently female than non-elderly patients (33.6% vs. 17.1%, p<0.001). As expected, the elderly patients had higher prevalence of chronic kidney disease (43.4% vs. 7.9%, p<0.001), had higher anatomical SYNTAX score (30.2±11.8 vs 28.0±11.2 p<0.001) when compared to those of the non-elderly patients. Up to 10 years, all-cause death occurred in 42.7% and 18.9% in the elderly and non-elderly patients, respectively (Log-rank p<0.001). The cubic spline curve showed an exponentially increase in all-cause death at 10 years according to the increase of age both in the PCI arm and the CABG arm. At 10 years, there was no significant difference in the risk of all-cause death between CABG vs. PCI either in elderly patients (41.5% vs. 44.0%; Log-rank p=0.53) or non-elderly patients (16.6% vs. 21.1%; Log-rank p=0.051). Conclusion CABG and PCI were equipoise in terms of risk of all-cause death at 10 years in patients with de novo 3VD and/or LMCAD irrespective of their age when stratified according to the prespecified threshold of 70 years old. Kaplan-Meier curves Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): German Foundation of Heart Research
Treatment of complex coronary artery disease in patients with diabetes mellitus and chronic kidney disease: 10-year results comparing outcomes of CABG and PCI in the SYNTAXES trial
Gao, Chao , Wang, R.T, Kawashima, Hideyuki , Geuns, Robert‐Jan van , Morice, Marie‐Claude, Davierwala, Piroze , Holmes, David R. , Mack, Michael J. , Mohr, F. W. , Thuijs, Daniel J.F.M. , Gao, Chao , Takahashi, Kuniaki , Onuma, Yoshinobu , Kappetein, A. Pieter , Head, S, Serruys, Patrick W.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2520 Get It

Abstract Background The SYNTAX Extended Survival (SYNTAXES) study is an investigator-driven extension of follow-up of the SYNTAX trial, which was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel and left main coronary artery disease. The SYNTAXES study is the first randomized trial that reported the complete 10-year data on all-cause death in patients with complex coronary artery disease. Purpose Patients with coronary artery disease (CAD) and concomitant diabetes mellitus (DM) or chronic kidney disease (CKD) are more susceptible to major adverse cardiovascular and cerebrovascular events. However, to date, the long-term prognosis and which revascularization strategy was associated with better clinical outcomes for patients with complex coronary artery disease and concomitant with DM and CKD have not been documented. Methods In this sub-analysis of the SYNTAXES trial, a total of 1,638 patients were classified into four subgroups according to the DM and CKD status: DM−/CKD− (n=999, 60.1%), DM+/CKD− (n=323, 19.7%), DM−/CKD+ (n=231, 14.1%), and DM+/CKD+ (n=85, 5.2%). The treatment effects of PCI and CABG were analyzed in each subgroup. The primary endpoint was all-cause death at 10 years. Results Compared with the DM−/CKD− patients, patients with DM+/CKD+ were older, more often had a history of stroke, hypertension, heart failure, and were more frequently presented with total occlusion, bifurcation lesion and three-vessel disease. At 10 years, patients with DM+/CKD+ had a 3.94-fold higher incidence of all-cause mortality compared with DM−/CKD− individuals (54.1% versus 18.9%, 95% CI [2.85–5.44]). Patients with DM−/CKD+ (38.1%, HR 2.36; 95% CI [1.83–5.44]) or DM+/CKD− (28.2%, HR 1.61; 95% CI [1.26–2.07]) had intermediate risk profile. For DM+/CKD+ patients, compared with PCI, those who underwent CABG were associated with lower incidence of all-cause mortality (64.3% versus 44.2%, adjusted HR 0.52; 95% CI [0.27–0.99], p=0.047, pinteraction=0.443). The number of needed-to-treat to reduce mortality for CABG was 12. Conclusion In the SYNTAX population, patients with DM and CKD are at markedly increased risk of long-term mortality rate compared with patients one or neither of these risk factors. For patients with both comorbidities, CABG was associated with better clinical outcome compared with PCI. These findings should be interpreted as hypothesis-generating. Figure 1. Kaplan-Meier curves showing the clinical events according to treatment and DM/CKD status. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Boston Scientific Corporation
Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
Polydefkis, Michael , Sekijima, Yoshiki , Sweetser, Marianne T., Arum, Seth, Wang, J.J, White, Matthew T. , Maurer, Mathew S. , Gillmore, Julian D. , Berk, John L. , Dispenzieri, Angela , González-Duarte, Alejandra , Maurer, Mathew S

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2129 Get It

Abstract Background/Introduction Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, life-threatening disease; the majority of patients develop a mixed phenotype of polyneuropathy and cardiomyopathy. Patisiran halted or reversed polyneuropathy and improved quality of life in the Phase 3 (APOLLO) study. In a prespecified cardiac subpopulation of APOLLO, patisiran also improved cardiac structure and function versus placebo. Purpose To describe the long-term comprehensive, integrated safety data from the patisiran clinical development program in patients with hATTR amyloidosis with polyneuropathy. Methods Safety data as of October 7, 2019 from the Phase 2 Open-Label Extension (OLE) (NCT01961921), Phase 3 APOLLO (NCT01960348), and ongoing Global OLE (NCT02510261) studies were analysed. Results Across the three studies, 224 patients received patisiran for a mean (range) of 43.6 (0.7–71.7) months, with a cumulative 813.9 patient-years of exposure; 105 (46.9%) patients received patisiran for ≥4 years and 35 (15.6%) patients received patisiran for ≥5 years. In this cohort, 149 (66.5%) had medical histories of cardiac disorders per MedDRA System Organ Class (SOC), which may be reflective of a mixed phenotype in some patients. A total of 222 (99.1%) patients experienced at least one adverse event (AE) and 132 (58.9%) patients experienced at least one serious AE. AEs considered to be related to patisiran and occurring in >5% of patients included infusion-related reactions (IRRs) (25.9%) and diarrhoea (6.3%). Cardiac AEs occurring in >5% of patients included atrial fibrillation (10.7%) and cardiac failure (7.6%). Amongst all patients, the exposure-adjusted mortality rate was 4.3 deaths per 100 patient-years. Conclusions Patients with hATTR amyloidosis with polyneuropathy in the patisiran clinical development program represent those with the longest treatment with an RNAi therapeutic, including more than 15% of patients receiving patisiran for ≥5 years. Patisiran continues to demonstrate a positive benefit:risk profile in patients with hATTR amyloidosis with polyneuropathy. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Alnylam Pharmaceuticals
Impact of periprocedural myocardial infarction on 10-year mortality after percutaneous coronary intervention or coronary artery bypass grafting for multivessel or left main coronary artery disease
Hara, Hironori , Gao, Chao , Wang, R, Kappetein, P, Mohr, F. W. , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Davierwala, Piroze , Thuijs, Daniel J.F.M. , Takahashi, Kuniaki , Ono, Masafumi , Head, S, Onuma, Yoshinobu , Serruys, Patrick W.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2491 Get It

Abstract Background Periprocedural myocardial infarction (PMI) occurs frequently after both percutaneous coronary intervention (PCI) and bypass grafting surgery (CABG) in patients with complex coronary artery disease (CAD), and PMI has been shown to have a detrimental impact on mortality. On the other hand, long-term impact of PMI on mortality has not been fully evaluated. Purpose This study aimed to assess the impact of PMI according to SCAI definition on 10-year all-cause death in patients with complex CAD. Methods The SYNTAX Extended Survival (SYNTAXES) study evaluated vital status up to 10 years in 1800 patients with de novo three-vessel disease and/or left main coronary artery disease randomized to treatment with CABG or PCI in the SYNTAX trial. Blood was sampled for creatine kinase (CK) pre- and post-revascularisation, and the cardiac specific MB iso-enzyme (CK-MB) was determined only if the CK ratio ≥2 x the upper limit of normal (ULN). If the CK ratio <2 ULN, CK-MB assessment was not mandated. In this analysis, patients with at least one blood sampling within 48 hours of the procedure were included. PMI was defined as follows; peak CK-MB measured within 48 hours of the procedure ≥10 x ULN, or ≥5 x ULN with new Q-waves in 2 contiguous leads or new persistent left bundle branch block. Results Of 1800 patients, 1679 (93.2%) patients were included. Of 877 patients treated with PCI, PMI occurred in 26 patients (3.0%), whereas 14 (1.7%) PMIs were observed in 802 patients treated with CABG. Compared with patients without PMI, patients with PMI presented with unstable angina more frequently (45.0% vs. 28.7, p=0.033), and had a higher rate of bifurcation lesion (87.5% vs. 72.5, p=0.046). PMI was associated with a higher all-cause mortality at 10 years compared with no PMI (55.3% vs. 25.4%; Log-rank p<0.001, Figure), which was mainly driven by a high mortality rate within 1 year. In patients undergoing PCI, the mortality rates were significantly higher in patients with PMI not only within 1 year (Log-rank p<0.001) but also beyond one year (Log-rank p=0.016), compare to patients without PMI (Figure). On the other hand, in patients undergoing CABG, a higher mortality rate in patients with PMI was observed until 1 year (Log-rank p<0.001), but the impact of PMI on mortality beyond one year after CABG subsided (Log-rank p=0.308) (Figure 1). Conclusion PMI was associated with a poor prognosis at 10 years. The impact of PMI on mortality was strong within one year. Of note, the impact of PMI on mortality persisted beyond 1 year only in patients undergoing PCI. Patients who were treated with PCI and suffered PMI need careful follow-up beyond one year after revascularization. Figure 1 Funding Acknowledgement Type of funding source: None
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer
Lehrer, Eric J. , Singh, Raj , Meng, Mao-Bin, Tchelebi, Leila T. , Tchelebi, Leila , Wang, Ming , Chinchilli, Vernon M , Trifiletti, Daniel M. , Ost, Piet , Siva, Shankar , Zaorsky, Nicholas G.

Mayo Clinic

JAMA Oncology | November 25, 2020 | Volume: 7 | Issue: 1 | Pages: 92

10.1001/jamaoncol.2020.6146 | PMID 33237270 Get It

International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, Richard R. , Kingdom, Todd T. , Smith, Timothy L. , Bleier, Benjamin S. , DeConde, Adam S., Luong, Amber , Poetker, David M., Welch, Kevin C. , Wise, Sarah K. , Adappa, Nithin D. , Anselmo‐Lima, Wilma Terezinha , Bachert, Claus , Baroody, Fuad M. , Batra, Pete S., Bernal‐Sprekelsen, Manuel , Bhattacharyya, Neil , Chang, Eugene H., Chowdhury, Naweed I. , Citardi, Martin J. , Cohen, Noah , Conley, David B. , DelGaudio, John M. , Desrosiers, Martin , Douglas, Richard , Eloy, Jean Anderson , Gray, Stacey T. , Gudis, David A. , Hamilos, Daniel L. , Han, Joseph K., Harvey, Richard J. , Hellings, Peter W. , Hopkins, Claire , Hwang, Peter H. , Javer, Amin R. , Kennedy, David W. , Kern, Robert C. , Lee, Heung‐Man , Lee, Jivianne T. , Levy, Joshua M. , Lin, Sandra Y. , Lund, Valerie, McMains, Kevin C. , Metson, Ralph, Naclerio, Robert M. , Oakley, Gretchen M. , Otori, Nobuyoshi , Parikh, Sanjay R., Patel, Zara M. , Peters, Anju T. , Philpott, Carl , Roh, Hwan‐Jung , Rudmik, Luke , Sacks, Raymond , Schlosser, Rodney J. , Sedaghat, Ahmad R. , Senior, Brent A. , Sindwani, Raj , Smith, Kristine A. , Stewart, Michael G. , Suh, Jeffrey D. , Tan, Bruce K. , Drunen, Cornelis M. van , Woodworth, Bradford A. , Wormald, Peter‐John , Wright, Erin D. , Yan, Carol H. , Zhang, Luo , Zhou, Bing , Chang, Michael T. , Bleier, Benjamin , Alt, Jeremiah A , Beswick, Daniel , Eloy, Jean Anderson , Gudis, David A , Holbrook, Eric H , Hopkins, Claire , Javer, Amin R , Jiang, Rong-San , Lal, Devyani , Lee, Heung-Man , Levy, Joshua M , Patel, Zara , Philpott, Carl , Ramakrishnan, Vijay R , Smith, Kristine , Yan, Carol , Zhang, Luo , Schlosser, Rodney J , Harvey, Richard J , Hwang, Peter H , Chang, Michael T , Soler, Zachary M. , Adappa, Nithin D. , Alt, Jeremiah A. , Beswick, Daniel M. , Chandra, Rakesh Kumar , Chang, Eugene H., Chiu, Alexander G. , Cohen, Noam A., Fokkens, Wytske Johanna , Holbrook, Eric H. , Laidlaw, Tanya M. , Lal, Devyani , Lane, Andrew P , Mullol, Joaquim , Passàli, Desiderio , Psaltis, Alkis J. , Ramanathan, Murugappan , Snidvongs, Kornkiat , Turner, Justin H. , Voegels, Richard Louis , Wang, De Yun

Mayo Clinic

International Forum of Allergy & Rhinology | November 25, 2020 | Volume: 11 | Issue: 3 | Pages: 213-739

10.1002/alr.22741 | PMID 33236525 Get It

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Sena, Laura A. , Fountain, Julia , Lim, Su Jin , Nizialek, Emily , Rathi, Nityam , Maughan, Benjamin L. , Vélez, Miguel González , Ashkar, Ryan, Larson, Amanda , Bryce, Alan H. , Agarwal, Neeraj , Pardoll, Drew M. , Eshleman, James R. , Antonarakis, Emmanuel S. , Antonarakis, Emmanuel S. , Bryce, Alan H , Antonarakis, Emmanuel S , Antonarakis, Emmanuel S , Velho, Pedro Isaacsson , Wang, Hao , Nussenzveig, Roberto , Larson, Amanda C., Pritchard, Colin C. , Adra, Nabil , Agarwal, Neeraj , Lotan, Tamara Levin

Mayo Clinic

The Oncologist | November 20, 2020 | Volume: 26 | Issue: 2 | Pages: e270-e278

10.1002/onco.13601 | PMID 33215787 Get It

Abstract Background Genomic biomarkers that predict response to anti-PD1 therapy in prostate cancer are needed. Frameshift mutations are predicted to generate more neoantigens than missense mutations; therefore, we hypothesized that the number or proportion of tumor frameshift mutations would correlate with response to anti-PD1 therapy in prostate cancer. Methods To enrich for response to anti-PD1 therapy, we assembled a multicenter cohort of 65 men with mismatch repair-deficient (dMMR) prostate cancer. Patient characteristics and outcomes were determined by retrospective chart review. Clinical somatic DNA sequencing was used to determine tumor mutational burden (TMB), frameshift mutation burden, and frameshift mutation proportion (FSP), which were correlated to outcomes on anti-PD1 treatment. We subsequently used data from a clinical trial of pembrolizumab in patients with nonprostatic dMMR cancers of various histologies as a biomarker validation cohort. Results Nineteen of 65 patients with dMMR metastatic castration-resistant prostate cancer were treated with anti-PD1 therapy. The PSA50 response rate was 65%, and the median progression-free survival (PFS) was 24 (95% confidence interval 16–54) weeks. Tumor FSP, more than overall TMB, correlated most strongly with prolonged PFS and overall survival (OS) on anti-PD1 treatment and with density of CD8+ tumor-infiltrating lymphocytes. High FSP similarly identified patients with longer PFS as well as OS on anti-PD1 therapy in a validation cohort. Conclusion Tumor FSP correlated with prolonged efficacy of anti-PD1 treatment among patients with dMMR cancers and may represent a new biomarker of immune checkpoint inhibitor sensitivity. Implications for Practice Given the modest efficacy of immune checkpoint inhibition (ICI) in unselected patients with advanced prostate cancer, biomarkers of ICI sensitivity are needed. To facilitate biomarker discovery, a cohort of patients with DNA mismatch repair-deficient (dMMR) prostate cancer was assembled, as these patients are enriched for responses to ICI. A high response rate to anti-PD1 therapy in these patients was observed; however, these responses were not durable in most patients. Notably, tumor frameshift mutation proportion (FSP) was identified as a novel biomarker that was associated with prolonged response to anti-PD1 therapy in this cohort. This finding was validated in a separate cohort of patients with nonprostatic dMMR cancers of various primary histologies. This works suggests that FSP predicts response to anti-PD1 therapy in dMMR cancers, which should be validated prospectively in larger independent cohorts.